Research article summary (published 12 Sep 2007):

Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues.

Full Abstract

BACKGROUND: Capecitabine is a recently developed oral antineoplastic prodrug of 5-fluorouracil. It has demonstrated a favorable tolerability profile, with low incidence of myelosuppression. Vinorelbine, a third generation vinca alkaloid, works by inhibiting mitosis and interfering with cells' ability to synthesize DNA and RNA. The present study investigates the therapeutic value of single use capecitabine on solid tumour tissues in vitro using breast cancer cell lines and as reference. The data is to be compared with the use of vinorelbine which is a conventionally applied drug for advanced breast cancer patients. METHODS: The trucut biopsies of 35 metastatic breast tumour patients were obtained. The tissues were cultured for 24h. Capecitabine and vinorelbine were added according to the corresponding groups to be cultured by another 24h. Plain medium was added for control group. The two cell lines chosen were BT-783 and MB-MDA-231 to act as a reference group. The metabolic rate of the tissues and cell lines were measured by ATP bioluminescence assay and the proliferation rate was measured by WST-1. The level of COX2 and p16 after capecitabine and vinorelbine treatment was assessed with immunohistochemical methods. RESULTS: One-way ANOVA revealed lower metabolic rate in test groups than control in cell lines and tumour tissues. WST-1 showed similar trend in both cell lines. COX2 and p16 staining showed decreases in cell size and number after drug use. CONCLUSIONS: Capecitabine demonstrated similar inhibitory effects as vinorelbine in breast cancer cell lines and solid tumour tissues at decreasing cell proliferation and metabolism as well as decreasing the expression of metabolic proteins and tumor suppressor genes. Capecitabine also has the added benefits of convenient oral administration and lower cost.

Author information

Author/s: Loo, Wings T Y (WT); Sasano, H (H); Chow, Louis W C (LW);

Affiliation: Department of Pathology, Tohuku University School of Medicine, Sendai, Japan.

Journal and publication information

Publication Type: Journal Article

Journal: Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie (Biomed Pharmacother), published in France. (Language: eng)

Reference: 2007-Oct; vol 61 (issue 9) : pp 596-600

Dates: Created 2007/10/22; Completed 2008/02/05;

PMID: 17904787, status: MEDLINE (last retrieved date: 2/18/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Adenosine Triphosphate - metabolism Antimetabolites, Antineoplastic - pharmacology Antineoplastic Agents, Phytogenic - pharmacology Breast Neoplasms - drug therapy; metabolism; pathology Cell Line, Tumor Cell Proliferation - drug effects Cyclin-Dependent Kinase Inhibitor p16 - biosynthesis Cyclooxygenase 2 - biosynthesis Deoxycytidine - analogs & derivatives; pharmacology

Deoxycytidine - analogs & derivatives; pharmacology Female Fluorouracil - analogs & derivatives; pharmacology Humans Immunohistochemistry Kinetics Luminescence Tetrazolium Salts - metabolism Vinblastine - analogs & derivatives; pharmacology

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (0) ; Antimetabolites, Antineoplastic (0) ; Antineoplastic Agents, Phytogenic (0) ; Cyclin-Dependent Kinase Inhibitor p16 (0) ; Tetrazolium Salts (0) ; capecitabine (154361-50-9) ; Fluorouracil (51-21-8) ; Adenosine Triphosphate (56-65-5) ; vinorelbine (71486-22-1) ; Vinblastine (865-21-4) ; Deoxycytidine (951-77-9) ; Cyclooxygenase 2 (EC 1.14.99.1)

Related articles

These are the most related articles currently in our database:

• Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. 4 May 2002
• Growth inhibition and apoptosis induction in ovarian cancer cells. 30 Jul 2006
• 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. 29 Apr 2004
• Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. 29 Oct 2007
• Incorporating oral capecitabine into the treatment of breast cancer. Introduction. 30 Dec 2001
• Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma tissues and cell lines in vitro. 12 Sep 2007
• Cytotoxic effects of haplamine and its major metabolites on human cancer cell lines. 27 Jul 2008
• The evolving role of capecitabine in breast cancer. 30 Mar 2003
• Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). 19 Apr 2005
• Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer. 30 May 2001

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a larger map of 100+ related articles.